Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma

February 14th 2025, 5:22pm

Transplantation and Cellular Therapy Meetings

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Zamto-Cel Delivers Responses in R/R Diffuse Large B-Cell Lymphoma

February 14th 2025, 4:22pm

Transplantation and Cellular Therapy Meetings

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025, 2:00am

Genitourinary Cancers Symposium (ASCO GU)

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

February 14th 2025, 1:13am

Genitourinary Cancers Symposium (ASCO GU)

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025, 12:34am

Genitourinary Cancers Symposium (ASCO GU)

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume

February 13th 2025, 10:49pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer

February 13th 2025, 10:22pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC

February 13th 2025, 10:15pm

Genitourinary Cancers Symposium (ASCO GU)

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

G-CSF Allows for Efficacious Dose of Docetaxel With ARASENS Regimen in mHSPC

February 13th 2025, 9:46pm

Genitourinary Cancers Symposium (ASCO GU)

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Boosts OS in mCRPC

February 13th 2025, 9:42pm

Genitourinary Cancers Symposium (ASCO GU)

Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.

Anakinra Fails to Reduce CRS, ICANS Associated With Liso-Cel in LBCL

February 13th 2025, 6:58pm

Transplantation and Cellular Therapy Meetings

Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

February 13th 2025, 6:45pm

Miami Cancer Institute Precision Oncology Symposium

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

February 13th 2025, 6:40pm

Miami Cancer Institute Precision Oncology Symposium

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

NKTR-255 Plus Anti-CD19 CAR T-Cell Therapy Demonstrates Safety and Preliminary Efficacy in R/R LBCL

February 13th 2025, 5:41pm

Transplantation and Cellular Therapy Meetings

NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.

Obe-Cel Is Associated With Improved Outcomes in R/R B-ALL With Low-Risk CAR-HT Scores

February 13th 2025, 5:10pm

Transplantation and Cellular Therapy Meetings

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025, 11:06pm

Genitourinary Cancers Symposium (ASCO GU)

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas

February 12th 2025, 9:18pm

Miami Cancer Institute Precision Oncology Symposium

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

February 12th 2025, 12:42am

PER® International Symposium on Melanoma and Other Cutaneous Malignancies

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

February 11th 2025, 11:04pm

PER® International Symposium on Melanoma and Other Cutaneous Malignancies

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma

February 11th 2025, 10:59pm

PER® International Symposium on Melanoma and Other Cutaneous Malignancies

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.